个人中心 - 老虎社区

miyakos

IP属地：未知

帖子 · 87帖子 · 87
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- miyakosmiyakos
  ·2021-09-14
  Latest
  FuelCell shares Popped 30% in morning trading
  FuelCell shares Popped 30% in morning trading on topping results forecasts. FuelCell reported a rar
  FuelCell shares Popped 30% in morning trading
  1,329 评论
  3
  分享
  举报
- miyakosmiyakos
  ·2021-09-13
  Latest
  非常抱歉，此主贴已删除
  1,174 1
  2
  分享
  举报
- miyakosmiyakos
  ·2021-09-09
  Latest
  非常抱歉，此主贴已删除
  1,263 评论
  5
  分享
  举报
- miyakosmiyakos
  ·2021-09-08
  Latest
  非常抱歉，此主贴已删除
  989 4
  6
  分享
  举报
- miyakosmiyakos
  ·2021-09-07
  Latest
  非常抱歉，此主贴已删除
  1,050 评论
  3
  分享
  举报
- miyakosmiyakos
  ·2021-09-06
  Latest
  This Could Be Novavax's Ace in the Hole
  Hint: It's not the company's COVID-19 vaccine. Key Points Novavax put its flu vaccine program on t
  This Could Be Novavax's Ace in the Hole
  669 评论
  3
  分享
  举报
- miyakosmiyakos
  ·2021-09-05
  Latest
  非常抱歉，此主贴已删除
  1,666 1
  7
  分享
  举报
- miyakosmiyakos
  ·2021-09-02
  Yeah
  非常抱歉，此主贴已删除
  1,836 评论
  4
  分享
  举报
- miyakosmiyakos
  ·2021-09-01
  Yes
  非常抱歉，此主贴已删除
  1,229 评论
  1
  分享
  举报
- miyakosmiyakos
  ·2021-08-31
  Latest
  非常抱歉，此主贴已删除
  874 评论
  2
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4088416347172780","uuid":"4088416347172780","gmtCreate":1625317032982,"gmtModify":1625317032982,"name":"miyakos","pinyin":"miyakos","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":9,"headSize":5,"tweetSize":87,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":882081815,"gmtCreate":1631631128137,"gmtModify":1631890297396,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/882081815","repostId":"1185574136","repostType":4,"repost":{"id":"1185574136","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631630152,"share":"https://www.laohu8.com/m/news/1185574136?lang=&edition=full","pubTime":"2021-09-14 22:35","market":"us","language":"en","title":"FuelCell shares Popped 30% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1185574136","media":"Tiger Newspress","summary":"FuelCell shares Popped 30% in morning trading on topping results forecasts.\n\nFuelCell reported a rar","content":"<p>FuelCell shares Popped 30%&nbsp;in morning trading&nbsp;on&nbsp;topping results forecasts.</p>\n<p><img src=\"https://static.tigerbbs.com/d07b75f01716e7feb7fed0f8f5a9c300\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>FuelCell&nbsp;reported a rare narrower-than-expected fiscal third-quarter net loss, helped by higher gross margin, and revenue that rose above forecasts. The net loss narrowed to $12.8 million, or 4 cents a share, from $16.1 million, or 7 cents a share, in the same period a year ago. That beat the FactSet consensus for per-share losses of 5 cents, to snap a seven-quarter streak of wider-than-expected losses. Revenue rose 43.2% to $26.8 million from $18.7 million, above the FactSet consensus of $21.1 million, boosted by a $7.2 million increase in service agreements and license revenue. Gross margin improved to positive 4.1% from negative 16.7%. The stock has tumbled 49.7% year to date through Monday, while the S&amp;P 500 has gained 19.0%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FuelCell shares Popped 30% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFuelCell shares Popped 30% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-14 22:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FuelCell shares Popped 30%&nbsp;in morning trading&nbsp;on&nbsp;topping results forecasts.</p>\n<p><img src=\"https://static.tigerbbs.com/d07b75f01716e7feb7fed0f8f5a9c300\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>FuelCell&nbsp;reported a rare narrower-than-expected fiscal third-quarter net loss, helped by higher gross margin, and revenue that rose above forecasts. The net loss narrowed to $12.8 million, or 4 cents a share, from $16.1 million, or 7 cents a share, in the same period a year ago. That beat the FactSet consensus for per-share losses of 5 cents, to snap a seven-quarter streak of wider-than-expected losses. Revenue rose 43.2% to $26.8 million from $18.7 million, above the FactSet consensus of $21.1 million, boosted by a $7.2 million increase in service agreements and license revenue. Gross margin improved to positive 4.1% from negative 16.7%. The stock has tumbled 49.7% year to date through Monday, while the S&amp;P 500 has gained 19.0%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185574136","content_text":"FuelCell shares Popped 30% in morning trading on topping results forecasts.\n\nFuelCell reported a rare narrower-than-expected fiscal third-quarter net loss, helped by higher gross margin, and revenue that rose above forecasts. The net loss narrowed to $12.8 million, or 4 cents a share, from $16.1 million, or 7 cents a share, in the same period a year ago. That beat the FactSet consensus for per-share losses of 5 cents, to snap a seven-quarter streak of wider-than-expected losses. Revenue rose 43.2% to $26.8 million from $18.7 million, above the FactSet consensus of $21.1 million, boosted by a $7.2 million increase in service agreements and license revenue. Gross margin improved to positive 4.1% from negative 16.7%. The stock has tumbled 49.7% year to date through Monday, while the S&P 500 has gained 19.0%.","news_type":1,"symbols_score_info":{"FCEL":0.9}},"isVote":1,"tweetType":1,"viewCount":1329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888750587,"gmtCreate":1631532248849,"gmtModify":1631890297413,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/888750587","repostId":"1133730816","repostType":4,"isVote":1,"tweetType":1,"viewCount":1174,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883019705,"gmtCreate":1631188037807,"gmtModify":1631890297422,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/883019705","repostId":"2166312201","repostType":4,"isVote":1,"tweetType":1,"viewCount":1263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889316628,"gmtCreate":1631109353464,"gmtModify":1631890297432,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/889316628","repostId":"1131499618","repostType":4,"isVote":1,"tweetType":1,"viewCount":989,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880987948,"gmtCreate":1631009921884,"gmtModify":1631890297446,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/880987948","repostId":"2165330144","repostType":4,"isVote":1,"tweetType":1,"viewCount":1050,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":817838648,"gmtCreate":1630929051884,"gmtModify":1631890297459,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/817838648","repostId":"1121589231","repostType":4,"repost":{"id":"1121589231","kind":"news","pubTimestamp":1630927585,"share":"https://www.laohu8.com/m/news/1121589231?lang=&edition=full","pubTime":"2021-09-06 19:26","market":"us","language":"en","title":"This Could Be Novavax's Ace in the Hole","url":"https://stock-news.laohu8.com/highlight/detail?id=1121589231","media":"Motley Fool","summary":"Hint: It's not the company's COVID-19 vaccine.\n\nKey Points\n\nNovavax put its flu vaccine program on t","content":"<blockquote>\n <b>Hint: It's not the company's COVID-19 vaccine.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Novavax put its flu vaccine program on the back burner after shifting to focus on COVID-19 in 2020.</li>\n <li>The company has already reported positive results from a late-stage study of its experimental NanoFlu flu vaccine.</li>\n <li>Novavax is moving forward with testing a COVID-19/flu combo that could potentially set the company apart from other vaccine makers.</li>\n</ul>\n<p><b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> </b>has its skeptics. Some point to the company's history of failure. Its respiratory syncytial virus (RSV) vaccine candidate ResVax experienced two clinical setbacks, and it haspushed back its anticipated timelinefor filing for Emergency Use Authorizations (EUAs) of its COVID-19 vaccine candidate NVX-CoV2373 three times.</p>\n<p>However, the future for this biotech stock could be brighter than many critics think. Novavax should file for EUA in the U.K. for NVX-CoV2373 within weeks, followed quickly by filings in the European Union and other countries.</p>\n<p>Its COVID-19 vaccine, while somewhat late to the party, could still be a commercial success for Novavax. But there's also another candidate in the company's pipeline that just might be its ace in the hole.</p>\n<p><b>A hot candidate on the back burner</b></p>\n<p>With all of the hubbub over NVX-CoV2373, it's easy to forget that it wasn't all that long ago that investors were excited about another experimental vaccine developed by Novavax. The company had high hopes for flu vaccine candidate NanoFlu after reporting encouraging results in early 2018 from a phase 1/2 study.</p>\n<p>Novavax advanced NanoFlu into phase 2 testing in older adults in September 2018. It reported more good news from that clinical trial in January 2019.</p>\n<p>That set the stage for NanoFlu's phase 3 study -- a head-to-head comparison with<b>Sanofi</b>'s&nbsp;approved flu vaccine FluZone Quadrivalent. The study began in October 2019. The following March, Novavax announced positive results, with NanoFlu clearly beating FluZone in the study's primary and secondary endpoints.</p>\n<p>The company seemed to be set to move quickly to file for approval of NanoFlu. However, its flu vaccine program was pushed to the back burner with Novavax moving forward with its COVID-19 vaccine development.</p>\n<p><b>A compelling combo</b></p>\n<p>It made sense that Novavax chose to focus on its COVID-19 program. The opportunity was too great to ignore, and Novavax's resources could only be spread out so far. And with the U.S. government throwing $1.6 billion the company's way to develop NVX-CoV2373, a shift in priorities was a no-brainer.</p>\n<p>However, Novavax certainly hasn't forgotten about NanoFlu. The company thinks that a combination COVID-19/flu vaccine featuring NVX-CoV2373 and NanoFlu could be a winner.</p>\n<p>Novavax has already announced promising preclinical data evaluating a NanoFlu/NVX-CoV2373 combination vaccine. It plans to initiate a phase 1 study in Australia later this year to evaluate the experimental combo.</p>\n<p>NanoFlu truly could be the key to Novavax setting itself apart from other COVID-19 vaccine makers.<b>Pfizer</b>&nbsp;and<b>BioNTech</b>&nbsp;are working on a flu vaccine candidate, but it hasn't advanced into clinical testing yet.<b>Moderna</b>only recently began early-stage clinical studies of its experimental flu vaccine.</p>\n<p>Meanwhile, Novavax has already demonstrated NanoFlu's safety and efficacy. It's also already moving ahead with clinical testing of a COVID-19/flu combo vaccine, something that rivals haven't done yet. Should annual boosters for COVID-19 be needed in the future, a combo COVID-19/flu vaccine could provide a compelling value proposition. Novavax appears to be the leader on this front.</p>\n<p><b>A good bet?</b></p>\n<p>I understand why some might be skeptical about Novavax considering the company's past track record. However, the company is in a better position than ever to succeed. Novavax has already reported positive results for NVX-CoV2373 from late-stage studies in the U.K. and the U.S. The primary hurdle now is to complete the regulatory filings for the vaccine.</p>\n<p>Assuming Novavax wins EUAs, it should be set to make a boatload of money. The company recently signed a deal with the European Union to supply 100 million doses initially and up to 100 million additional doses of NVX-CoV2373. Novavax could soon have ample financial resources to fund its COVID-19/flu combo vaccine program.</p>\n<p>It's not surprising at all to me that analysts are bullish about thevaccine stock. With the attractive prospects for NVX-CoV2373 and NanoFlu as its ace in the hole, Novavax appears to be a pretty good bet.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Could Be Novavax's Ace in the Hole</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Could Be Novavax's Ace in the Hole\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-06 19:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/06/this-could-be-novavaxs-ace-in-the-hole/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hint: It's not the company's COVID-19 vaccine.\n\nKey Points\n\nNovavax put its flu vaccine program on the back burner after shifting to focus on COVID-19 in 2020.\nThe company has already reported ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/06/this-could-be-novavaxs-ace-in-the-hole/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/09/06/this-could-be-novavaxs-ace-in-the-hole/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121589231","content_text":"Hint: It's not the company's COVID-19 vaccine.\n\nKey Points\n\nNovavax put its flu vaccine program on the back burner after shifting to focus on COVID-19 in 2020.\nThe company has already reported positive results from a late-stage study of its experimental NanoFlu flu vaccine.\nNovavax is moving forward with testing a COVID-19/flu combo that could potentially set the company apart from other vaccine makers.\n\nNovavax has its skeptics. Some point to the company's history of failure. Its respiratory syncytial virus (RSV) vaccine candidate ResVax experienced two clinical setbacks, and it haspushed back its anticipated timelinefor filing for Emergency Use Authorizations (EUAs) of its COVID-19 vaccine candidate NVX-CoV2373 three times.\nHowever, the future for this biotech stock could be brighter than many critics think. Novavax should file for EUA in the U.K. for NVX-CoV2373 within weeks, followed quickly by filings in the European Union and other countries.\nIts COVID-19 vaccine, while somewhat late to the party, could still be a commercial success for Novavax. But there's also another candidate in the company's pipeline that just might be its ace in the hole.\nA hot candidate on the back burner\nWith all of the hubbub over NVX-CoV2373, it's easy to forget that it wasn't all that long ago that investors were excited about another experimental vaccine developed by Novavax. The company had high hopes for flu vaccine candidate NanoFlu after reporting encouraging results in early 2018 from a phase 1/2 study.\nNovavax advanced NanoFlu into phase 2 testing in older adults in September 2018. It reported more good news from that clinical trial in January 2019.\nThat set the stage for NanoFlu's phase 3 study -- a head-to-head comparison withSanofi's approved flu vaccine FluZone Quadrivalent. The study began in October 2019. The following March, Novavax announced positive results, with NanoFlu clearly beating FluZone in the study's primary and secondary endpoints.\nThe company seemed to be set to move quickly to file for approval of NanoFlu. However, its flu vaccine program was pushed to the back burner with Novavax moving forward with its COVID-19 vaccine development.\nA compelling combo\nIt made sense that Novavax chose to focus on its COVID-19 program. The opportunity was too great to ignore, and Novavax's resources could only be spread out so far. And with the U.S. government throwing $1.6 billion the company's way to develop NVX-CoV2373, a shift in priorities was a no-brainer.\nHowever, Novavax certainly hasn't forgotten about NanoFlu. The company thinks that a combination COVID-19/flu vaccine featuring NVX-CoV2373 and NanoFlu could be a winner.\nNovavax has already announced promising preclinical data evaluating a NanoFlu/NVX-CoV2373 combination vaccine. It plans to initiate a phase 1 study in Australia later this year to evaluate the experimental combo.\nNanoFlu truly could be the key to Novavax setting itself apart from other COVID-19 vaccine makers.Pfizer andBioNTech are working on a flu vaccine candidate, but it hasn't advanced into clinical testing yet.Modernaonly recently began early-stage clinical studies of its experimental flu vaccine.\nMeanwhile, Novavax has already demonstrated NanoFlu's safety and efficacy. It's also already moving ahead with clinical testing of a COVID-19/flu combo vaccine, something that rivals haven't done yet. Should annual boosters for COVID-19 be needed in the future, a combo COVID-19/flu vaccine could provide a compelling value proposition. Novavax appears to be the leader on this front.\nA good bet?\nI understand why some might be skeptical about Novavax considering the company's past track record. However, the company is in a better position than ever to succeed. Novavax has already reported positive results for NVX-CoV2373 from late-stage studies in the U.K. and the U.S. The primary hurdle now is to complete the regulatory filings for the vaccine.\nAssuming Novavax wins EUAs, it should be set to make a boatload of money. The company recently signed a deal with the European Union to supply 100 million doses initially and up to 100 million additional doses of NVX-CoV2373. Novavax could soon have ample financial resources to fund its COVID-19/flu combo vaccine program.\nIt's not surprising at all to me that analysts are bullish about thevaccine stock. With the attractive prospects for NVX-CoV2373 and NanoFlu as its ace in the hole, Novavax appears to be a pretty good bet.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":669,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814533960,"gmtCreate":1630840174950,"gmtModify":1631890297470,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/814533960","repostId":"2164803577","repostType":4,"isVote":1,"tweetType":1,"viewCount":1666,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812568610,"gmtCreate":1630595120830,"gmtModify":1631890297482,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Yeah","listText":"Yeah","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812568610","repostId":"2164821842","repostType":4,"isVote":1,"tweetType":1,"viewCount":1836,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816689882,"gmtCreate":1630495932646,"gmtModify":1631890297494,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/816689882","repostId":"2164894947","repostType":4,"isVote":1,"tweetType":1,"viewCount":1229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818206299,"gmtCreate":1630409504711,"gmtModify":1631890297508,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/818206299","repostId":"2163859671","repostType":4,"isVote":1,"tweetType":1,"viewCount":874,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}